Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP653086.RA_2VhMvDS1FJ67z732aAL89Nvn6N1lW3uBmc5ju0bONM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP653086.RA_2VhMvDS1FJ67z732aAL89Nvn6N1lW3uBmc5ju0bONM130_assertion type Assertion NP653086.RA_2VhMvDS1FJ67z732aAL89Nvn6N1lW3uBmc5ju0bONM130_head.
- NP653086.RA_2VhMvDS1FJ67z732aAL89Nvn6N1lW3uBmc5ju0bONM130_assertion description "[Sunitinib is currently being evaluated in advanced human thyroid carcinomas, based on the rationale that the vascular endothelial growth factor and platelet-derived growth factor receptors and the RET/PTC rearrangement are valuable targets for the treatment of this malignancy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP653086.RA_2VhMvDS1FJ67z732aAL89Nvn6N1lW3uBmc5ju0bONM130_provenance.
- NP653086.RA_2VhMvDS1FJ67z732aAL89Nvn6N1lW3uBmc5ju0bONM130_assertion evidence source_evidence_literature NP653086.RA_2VhMvDS1FJ67z732aAL89Nvn6N1lW3uBmc5ju0bONM130_provenance.
- NP653086.RA_2VhMvDS1FJ67z732aAL89Nvn6N1lW3uBmc5ju0bONM130_assertion SIO_000772 22442268 NP653086.RA_2VhMvDS1FJ67z732aAL89Nvn6N1lW3uBmc5ju0bONM130_provenance.
- NP653086.RA_2VhMvDS1FJ67z732aAL89Nvn6N1lW3uBmc5ju0bONM130_assertion wasDerivedFrom befree-20150227 NP653086.RA_2VhMvDS1FJ67z732aAL89Nvn6N1lW3uBmc5ju0bONM130_provenance.
- NP653086.RA_2VhMvDS1FJ67z732aAL89Nvn6N1lW3uBmc5ju0bONM130_assertion wasGeneratedBy ECO_0000203 NP653086.RA_2VhMvDS1FJ67z732aAL89Nvn6N1lW3uBmc5ju0bONM130_provenance.